Invest-in-America
3週前
TRAW: That old adage, to wit --- "The Best Laid Plans of MIce & Men" --- applies to the (fluff) PR last Friday by TRAW company. WHY?? Because their cheap "Phase-1" trial indicated that their Bird Pox therapeutic purportedly SAVED all those previously-infected MICE. (WOW!!! Glory to God on the highest!!!)
"Thanks, TRAW company, for saving my LIFE --- after I volunteered for your epic Phase-1 MIce Trial!!! And, I got 23-days of FREE CHEESE, during the 3-week trail!!! While all those HUMANS in the trial got one lousy McDonald's Happy Meal, once a day, while crashing at a cheap Motel-6 across the street from the hospital!!!"
PS: But, TRADE this classic snake oil NASDAQ firm anyway?? Sure!! Scam THEM, before they sucker YOU!! (I recommend, at best, a quick FLIP not more than circa 5-minutes into the Open starting gate tomorrow, at which time it may run-up quickly (& then crash). Or, if you have "WeBull" --- and are on the EAST COAST --- then play it in the Pre-Market tomorrow --- but NOT for me, way over here in San Diego, at 1:00 in the flucking dark morning!!!)
Invest-in-America
4週前
TRAW: Below is pasted some of my interaction with COPILOT regarding TRAW's (fluffy) PR last Friday ---
ME: "And even MORE worrisome is the lack of any mention at all as to were those Phase-1 Human subjects even INFECTED or EXPOSED to any manner of Bird Flu during that Phase-1 study. Very troubling."
COPILOT: "You're right, that is concerning. The Phase 1 study for Traws Pharma's bird flu drug, Tivoxavir Marboxil, was conducted on healthy, influenza-negative volunteers. This means the study didn't involve actual exposure to bird flu, which raises questions about the real-world efficacy of the drug. It's definitely something investors should keep an eye on as the company moves forward with Phase 2 studies. Do you think this lack of clarity might affect the company's credibility with investors?"
Invest-in-America
4週前
TRAW: I saw TRAW --- which spells WART, backwards --- yesterday (Post-M) at the top of my daily Post-M data source, as follows:
https://www.tradingview.com/markets/stocks-usa/market-movers-after-hours-gainers/
However, conspicuously MISSING from their PR is any beneficial EFFECT (if any) upon the Phase-1 trial SUBJECTS themselves --- other than the typical jargon about "safety" & "adverse effects". (I.e., a FLUFFY PR, at best.) Nevertheless, I may indeed toss BUCKS at it anyway, since we ALL know Wall Street is about making MONEY, and NOT nit-picking news nor PR's, RIGHT???)
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
TRAW (3.7-Mil. Flt., 0.1%): $8.06, 58%-Up; XXX ; (Post-M) news Bird Flu, Phase-1; Virology & Oncology, Penn.
tw0122
4週前
Live from SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (NASDAQ: TRAW) H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging results as a single-dose treatment for H5N1 avian influenza, representing a potentially pivotal advance in addressing this serious health challenge.
tw0122
1月前
"In laboratory testing, tivoxavir marboxil inhibited multiple isolates of highly pathogenic avian influenza H5N1. We evaluated the effects of drug treatment in mice exposed to human H5N1, where the virus was isolated from a dairy worker exposed to infected cattle," said C. David Pauza, PhD, Chief Science Officer for Traws Pharma. "Oral treatment with tivoxavir marboxil after the virus infection resulted in complete survival and lung virus levels below the limit of quantitation1. This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza.""Current topline data from our Phase I clinical trial demonstrated safety and tolerability of tivoxavir marboxil, and maintenance of drug levels in blood above the EC90 for longer than 23 days1, with topline data for a higher dose still to come," said Werner Cautreels, PhD, Chief Executive Officer of Traws Pharma. "In addition, the potential for tivoxavir marboxil as a treatment for H5N1 bird flu was demonstrated in an animal model."Topline Phase 1 Results with Tivoxavir Marboxil
The Phase 1 trial was a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics (PK) of ascending doses for one-time tivoxavir marboxil treatment in healthy, influenza-negative, adult volunteers. No treatment-related adverse events were reported during the Phase 1 study. Current topline data from this study showed that a single dose of tivoxavir marboxil maintained plasma drug levels consistently above the EC90 for more than twenty-three days, with topline data for a higher dose still to come. Preclinical studies showed that tivoxavir marboxil demonstrated potent inhibition of drug-resistant influenza viruses, as well as potent inhibition of highly pathogenic bird flu viruses1 both in vitro and in vivo.About H5N1 Bird FluThe virus, also known as Type A H5N1 was detected for the first time in U.S. dairy cattle in March 2024. Since then, bird flu has been confirmed in at least 866 herds in 16 states. More than 60 people in eight states have been infected according to the U.S. Centers for Disease Control and Prevention. Health officials confirmed in December 2024 the first known severe illness in the U.S. caused by bird flu7. The California governor declared a state of emergency as the virus rampages through dairy cattle in that state8.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
TheFinalCD
4週前
